Oligoprogression is considered in a situation in which an EGFR-mutant advanced NSCLC patient develops disease progression in one or a limited number of sites after an EGFR-TKI period of stable disease or an ORR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.